ALLO-715 is a Gene-Modified Cell Therapy owned by Allogene Therapeutics, and is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned.

ALLO-715 elicits immunostimulant activity. CARs are comprised of an antigen-binding domain, an extracellular spacer/hinge region, a transmembrane domain and an intracellular signaling domain resulting in T cell activation after antigen binding. B-cell maturation antigen (BCMA) is over-expressed in multiple myeloma. T cells bind to the BCMA surface antigen and result in a cytotoxic T-lymphocyte (CTL) response against BCMA-expressing cells.

The revenue for ALLO-715 is expected to reach a total of $2.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ALLO-715 NPV Report.

ALLO-715 was originated by Cellectis and is currently owned by Allogene Therapeutics.

ALLO-715 Overview

ALLO-715 is under development for the treatment of relapsed and refractory multiple myeloma. The therapeutic candidate constitutes autologous T cells modified to express chimeric antigen receptor (CAR) that target tumor cells expressing B cell maturation antigen (BCMA). The therapeutic candidate was developed based on TALEN gene-editing technology.

Allogene Therapeutics Overview

Allogene Therapeutics is a clinical stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes UCART19, ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the shelf allogeneic CAR T therapy candidate for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. The company seeks to partner with other companies in the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.

The company reported revenues of (US Dollars) US$38.5 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$255.8 million in FY2021, compared to an operating loss of US$258.2 million in FY2020. The net loss of the company was US$257 million in FY2021, compared to a net loss of US$250.2 million in FY2020.

Quick View – ALLO-715

Report Segments
  • Innovator
Drug Name
  • ALLO-715
Administration Pathway
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.